PairX develops cancer-selective biologics by identifying prevalent tumor-associated antigens derived from aberrantly spliced proteins, enabling targeted therapies that minimize off-target effects. This approach addresses the limited availability of effective treatment options for large patient populations by focusing on highly selective targets that improve therapeutic efficacy and tolerability.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments often lack specificity, leading to off-target effects and dose-limiting toxicities because existing therapeutic targets are also present on healthy tissue or are only found in small patient populations. This scarcity of cancer-selective targets limits effective treatment options for many patients.
Solution
PairX is developing cancer-selective biologics by identifying prevalent tumor-associated antigens derived from aberrantly spliced proteins. This variant-specific approach aims to create therapies that better discriminate between tumor and normal tissue, improving efficacy and tolerability. By focusing on cell surface variants present in substantial proportions of cancer patient populations, PairX seeks to address unmet needs in difficult-to-treat cancers. The company is advancing a pipeline of potential first- and best-in-class tumor-selective therapies.
Target Audience
The primary target audience includes patients with difficult-to-treat cancers and the clinicians who treat them.
Features
- Identification of novel, highly prevalent, tumor-selective cell surface variants as therapeutic targets.
- Focus on variants that play a functional role in carcinogenesis.
- Selection of highly actionable drug targets paired with optimal therapeutic modalities.
- Development of T-cell engagers (TCEs), antibody-drug conjugates (ADCs), radioligands, and bispecifics.